CD38/CD3 targeting shows a bright future for multiple myeloma immunotherapy.

Ethan Li Grade 11, Markville Secondary School, Markham, Canada Sun Life Gene Medical Science Institute Cancer Research Program Student, Toronto, Ontario, Canada.  

Journal of Sunlifegene Medical Science Research Volume 6 No.3 November 3,2024.  

There are a variety of diseases and malignancies that stem from blood cells. One of the most prevalent of these malignancies is Multiple Myeloma (MM) which originates from plasma cells. Over the past 20 years, patients have seen significant improvements in the treatment of MM but there has still yet to be a cure found. MM patient survival, measured by the median overall survival (MOS), has increased from 2 years to 5-6 years following the introduction of immunomodulatory drugs and proteasome inhibitors which have all been significant advancements in the field of MM treatment. Since 2012, multiple different treatments and therapies have been introduced such as new drugs, and CAR-T cell therapies which helps the immune system target MM cells. As of now, CD38/CD3 proteins related to MM, have been heavily targeted and researched and provide the answer to finally bridging the gap to find a potential cure for MM (1,2,3,4)